News
Nippon Kayaku's news releases are issued to inform our stakeholders of the latest information regarding the Company.
While some news releases may contain information about pharmaceutical products (including those under development), they are intended solely for disclosure purposes to members of the media, shareholders, and investors, and are not intended for advertising or promotional purposes, nor to provide medical advice.
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.


